ICON Public (NASDAQ:ICLR) Given New $330.00 Price Target at Evercore ISI

ICON Public (NASDAQ:ICLR) had its price objective cut by research analysts at Evercore ISI from $350.00 to $330.00 in a research report issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s price objective indicates a potential upside of 6.87% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Barclays increased their price target on shares of ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Truist Financial lifted their target price on ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a report on Friday, February 23rd. TD Cowen upped their price target on ICON Public from $343.00 to $349.00 and gave the stock a “buy” rating in a research note on Friday. Robert W. Baird lifted their price objective on ICON Public from $362.00 to $363.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Mizuho reissued a “buy” rating and set a $346.00 target price on shares of ICON Public in a research report on Thursday, April 4th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $321.64.

ICON Public Trading Up 2.9 %

Shares of NASDAQ:ICLR traded up $8.72 during midday trading on Friday, reaching $308.80. The company’s stock had a trading volume of 404,015 shares, compared to its average volume of 562,555. The business has a 50 day moving average price of $318.31 and a 200 day moving average price of $282.20. ICON Public has a 1 year low of $181.92 and a 1 year high of $344.77. The firm has a market cap of $25.48 billion, a price-to-earnings ratio of 37.54, a price-to-earnings-growth ratio of 1.46 and a beta of 1.15. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.40.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.13. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.84%. Research analysts forecast that ICON Public will post 14.4 EPS for the current year.

Institutional Trading of ICON Public

Large investors have recently modified their holdings of the business. Bruce G. Allen Investments LLC purchased a new position in ICON Public in the fourth quarter valued at about $25,000. Riverview Trust Co acquired a new position in shares of ICON Public in the 1st quarter valued at approximately $31,000. Livelsberger Financial Advisory purchased a new position in shares of ICON Public during the 4th quarter valued at approximately $29,000. Pinnacle Bancorp Inc. increased its stake in shares of ICON Public by 110.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock worth $30,000 after buying an additional 55 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new stake in ICON Public in the fourth quarter valued at $37,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.